The study was comprised of @ parts : in part @ , patients were randomized to either intravenous ( IV ) dinaciclib ( @ mg/m@ ) or oral erlotinib ( @ mg ) using an adaptive Bayesian design that adjusted the randomization ratio in favor of the more active arm , and in part @ , patients who had progressed on erlotinib were permitted to cross over to receive dinaciclib at the same dosage as in part @ .